Silexion Therapeutics Corp
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2026 | 2025 | |
|---|---|---|
| U.S. dollars in thousands | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(2,733) | $(1,735) |
| Adjustments required to reconcile loss to net cash used in operating activities: | ||
| Depreciation | 2 | 4 |
| Share-based compensation expenses | 345 | 21 |
| Non-cash financial expenses | 4 | 81 |
| Changes in operating assets and liabilities: | ||
| Increase in prepaid expenses | (959) | (512) |
| Decrease (increase) in other current assets | (47) | 4 |
| Increase (decrease) in trade payable | 125 | (207) |
| Net change in operating lease | (4) | (1) |
| Decrease in employee related obligations | (319) | (18) |
| Decrease in other accounts payable | (60) | (90) |
| Net cash used in operating activities | (3,646) | (2,453) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | - | (6) |
| Net cash used in investing activities | - | (6) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Issuance of Ordinary Shares under the At-the Market Sales Agreement, net of placement agent fee | 83 | - |
| Proceeds from issuance of ordinary shares upon January Offering | - | 5,000 |
| Issuance costs related to January Offering | - | (650) |
| Proceeds from exercise of warrants upon January Offering | - | 864 |
| Proceeds from issuance of ordinary shares upon January Inducement Offer | - | 3,276 |
| Issuance costs related to warrants inducement transaction | - | (362) |
| Payment of Underwriters Promissory Note | - | (696) |
| Net cash provided by financing activities | 83 | 7,432 |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (3,563) | 4,973 |
| EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (14) | (10) |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 6,075 | 1,270 |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | $2,498 | $6,233 |
F - 7
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2026 · 2025 | ||||
|---|---|---|---|---|
| U.S. dollars in thousands | ||||
| Appendix A – RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS: | ||||
| Cash and cash equivalents | 2,413 | 6,152 | ||
| Restricted cash | 85 | 81 | ||
| TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS | $2,498 | $6,233 | ||
| Appendix B - SUPPLEMENTARY INFORMATION: | ||||
| SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: | ||||
| Prepaid issuance expenses utilized, in respect of ATM Sales Agreement | $7 | $ | - | |
| Conversion of Promissory Note to ordinary shares | $ | - | $356 | |
| Accrued and unpaid issuance expenses in respect of public offering and warrants inducement transactions | $ | - | $195 | |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||
| Interest paid | $ | - | $13 | |
| Interest received | $32 | $2 | ||
F - 8
SILEXION THERAPEUTICS CORP NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (U.S. dollars in thousands)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.